COMP <GO>
THC vs JNJ // RSI-14 & 200D SMA MOMENTUM
Tenet Healthcare Corporation (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: THC 5
— JNJ 9
▲ RSI-14 & 200D SMA MOMENTUM LEADER: JNJ
LAST: $273.25 (+0.99%) • MKT CAP: $21.79B
rsi-technicals
58.2
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
rsi-technicals
60.4
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (THC VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | THC | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 67.90% | -26.90 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 27.60% | 25.50% | +2.10 | THC | /roic <GO> |
| EV/EBITDA & P/E Valuation | 6.3x | 18.5x | -12.20 | THC | /valuation <GO> |
| Free Cash Flow Yield | 11.61% | 2.97% | +8.64 | THC | /fcf-yield <GO> |
| Operating Margin | 16.50% | 34.70% | -18.20 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 11.10% | 28.50% | -17.40 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 3.10% | 6.00% | -2.90 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.08 | 5.59 | -3.51 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.80% | 7.20% | -0.40 | THC | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 58.2 | 60.4 | -2.19 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.97 | 1.08 | -0.11 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 8.6x | 23.0x | -14.40 | THC | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $21.79B | $662.49B | -$640.71B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | THC REV | JNJ REV | THC GROSS % | JNJ GROSS % | THC FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $21.31B | $94.19B | 44.0% | 67.9% | $2.53B | $19.70B |
| FY 2024 | $20.68B | $88.82B | 44.0% | 69.1% | $1.12B | $19.84B |
| FY 2023 | $20.56B | $85.16B | 44.0% | 44.0% | $1.45B | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
THC // BETA 0.97
JNJ // BETA 1.08